aTyr Pharma releases results of early-onset FSHD trial
[…] results from its Phase 1b/2 003 trial assessing the safety and potential activity of Resolaris™ in patients with early onset facioscapulohumeral muscular dystrophy ( FSHD). Read the full press release here.